Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
"There are no effective therapies for MDS after treatment failures of hypomethylating agents. Sapacitabine has demonstrated promising activity in this difficult to treat population which warrants further clinical development in MDS," said Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and study chair of the sapacitabine Phase 2 study.
"We are encouraged by the interim response data which indicates that sapacitabine is active in MDS patients after treatment with hypomethylating agents such as azacitidine or decitabine," said Judy H. Chiao, M.D., Cyclacel's Vice President, Clinical Development & Regulatory Affairs. "The primary efficacy endpoint of the study is 1-year survival. We look forward to reporting 1-year survival data toward the end of 2010."
Breakthrough in HWE reaction offers pathway for anti-cancer drug development